Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN016 in Advanced Non-small Cell Lung Cancer
NCT06775483Phase 2Not yet recruiting
- Sponsor
- Alphamab Oncology
- Start
- Jan 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, randomised, open-label trial of JSKN016 in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Alphamab Oncology. Primary endpoints: Objective Response Rate up to 24 months and Adverse Events up to 24 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
JSKN016
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06775483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775483.